Citations

Clear

390 citation(s) found for "Loftus, E".

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study
Singh, Siddharth , Loftus, Edward V. , Jess, Tine , Singh, S , Jess, T , Loftus, Edward V , Andersen, Nynne Nyboe , Andersson, Mikael

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 14, 2017 | Volume: 47 | Issue: 5 | Pages: 596-604

10.1111/apt.14466 | PMID 29239001 Get It

SummaryBackgroundThere are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn's disease (CD).AimsTo compare the effectiveness and safety of adalimumab and infliximab in biologic‐naïve patients with CD, in a nationwide register‐based propensity score‐matched cohort study in Denmark.MethodsA total of 2908 Danish adults with CD had been treated with adalimumab or infliximab as their first biologic agent between 2005‐2014. By Cox regression, we compared rates of all‐cause hospitalisation, CD‐related hospitalisation, major abdominal surgery and serious infections after variable 2:1 propensity score matching, accounting for baseline disease characteristics, healthcare utilisation and use of CD‐related medications.ResultsAfter propensity‐score matching, we included 315 adalimumab‐ (34.9 ± 12.9 years, 41.9% males) and 512 infliximab‐treated (33.6 ± 12.6 years, 40.8% males) patients, with median disease duration 4.0 years; 36.9% had prior abdominal surgery. Over a median follow‐up 2.3 years after starting biological therapy, there were no significant differences in rate of CD‐related hospitalisation (hazard ratio [HR], 0.81 [95% CI, 0.55‐1.20]) or major abdominal surgery (HR, 1.24 [0.66‐2.33]) between adalimumab‐ and infliximab‐treated patients, though rate of all‐cause hospitalisation was lower in adalimumab‐treated patients (HR, 0.74 [0.56‐0.97]). There was no significant difference in incidence of serious infections requiring hospitalisation (HR, 1.06 [0.26‐4.21]). These results were stable in patients treated with biological monotherapy (all‐cause hospitalisation: HR, 0.75 [0.53‐1.05]; CD‐related hospitalisation: HR, 0.82 [0.51‐1.32], abdominal surgery: HR, 1.47 [0.63‐3.47]) or in combination with immunomodulators (all‐cause hospitalisation: HR, 0.70 [0.44‐1.11]; CD‐related hospitalisation: HR, 0.80 [0.42‐1.52], abdominal surgery: HR, 1.02 [0.39‐2.64]).ConclusionsIn this population‐based, propensity score matched, real‐life cohort study using administrative claims, there was no significant difference in effectiveness and safety of adalimumab and infliximab in biologic‐naïve patients with CD.
A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion
Ding, Zonghui , Roos, Alison , Kloss, Jean , Peng, Sen, Pirrotte, Patrick , Eschbacher, Jennifer M., Tran, Nhan L. , Loftus, Joseph C. , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | November 8, 2017 | Volume: 16 | Issue: 2 | Pages: 322-332

10.1158/1541-7786.mcr-17-0454 | PMID 29117939 Get It

Abstract Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-κB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion. Mol Cancer Res; 16(2); 322–32. ©2017 AACR.
Identification and validation of functional gastrointestinal disorder subtypes using latent class analysis: a population-based study
Zinsmeister, Alan R., Herrick, Linda M., Saito, Yuri A. , Schleck, Cathy D. , Saito Loftus, Yuri A, Talley, Nicholas J.

Mayo Clinic

Scandinavian Journal of Gastroenterology | November 6, 2017 | Volume: 53 | Issue: 5 | Pages: 549-558

10.1080/00365521.2017.1395908 | PMID 29103329 Get It

Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study
Tremaine, William J., Raffals, Laura E. , Kane, Sunanda V. , Loftus, Edward V. , Aniwan, Satimai , Loftus, Edward V

Mayo Clinic

Journal of Crohn's and Colitis | September 22, 2017 | Volume: 12 | Issue: 2 | Pages: 137-144

10.1093/ecco-jcc/jjx135 | PMID 29029150 Get It

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply
Cotter, Thomas G. , Kamboj, Amrit K. , Hicks, Stephen B., Tremaine, William J., Loftus, Edward V. , Pardi, Darrell S. , Cotter, T G , Pardi, D S , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 14, 2017 | Volume: 46 | Issue: 6 | Pages: 636-636

10.1111/apt.14239 | PMID 28805323 Get It

Linked ContentThis article is linked to Cotter et al and Fernández‐Bañares and Gisbert papers. To view these articles visit https://doi.org/10.1111/apt.14133 and https://doi.org/10.1111/apt.14220.
The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease
Saffouri, George, Loftus, Edward V. , Pardi, Darrell S. , Khanna, Sahil , Loftus, Edward V , Gupta, Arjun , Baddour, Larry M.

Mayo Clinic

Scandinavian Journal of Gastroenterology | August 7, 2017 | Volume: 52 | Issue: 11 | Pages: 1240-1247

10.1080/00365521.2017.1362466 | PMID 28782372 Get It

Abstract 1878: PDZ-RhoGEF functions as a critical signaling effector for TROY
Roos, Alison , Kloss, Jean , Symons, Marc , Tran, Nhan L. , Loftus, Joseph C. , Ding, Zonghui , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1878-1878

10.1158/1538-7445.am2017-1878 Get It

Abstract Glioblastoma Multiforme (GBM) is the most common tumor of the CNS with a median survival of approximately 15 months. The highly aggressive invasion of malignant cells into the surrounding normal brain tissue renders complete surgical resection impossible, increases therapeutic resistance, and virtually assures tumor recurrence. We have previously demonstrated that TROY (TNFRSF19) has an important role in GBM invasion and resistance. TROY expression is correlated with glial tumor grade and inversely correlated with patient survival. Increased TROY expression stimulated cell migration/invasion in vitro and in vivo and confers resistance to both ionizing radiation- and temozolomide-induced apoptosis via activation of Akt and NF-κB. These data indicate that TROY stimulated migration/invasion is associated with signaling pathways that also increase survival and therapeutic resistance, however, the mechanistic basis of this signaling remains unclear. To investigate the mechanism by which TROY induces GBM cell invasion, we performed immunoprecipitation of the TROY receptor coupled with MALDI-TOF and MS/MS analysis and identified PDZ-RhoGEF as a binding partner for TROY. We validated the interaction of TROY with PDZ-RhoGEF by immunoprecipitation and western blotting, and demonstrated that PDZ-RhoGEF can exchange for both RhoA and RhoC in glioma cells and is implicated in GBM cell invasion, proliferation, and survival. In order to assess the specific role of PDZ-RhoGEF in TROY signaling, we examined the effects of PDZ-RhoGEF on TROY-mediated activation of NF-κB. While overexpression of TROY alone strongly stimulated NF-κB transcriptional activity in serum-free conditions, increased expression of PDZ-RhoGEF alone had no effect on NF-κB activity. Co-transfection of PDZ-RhoGEF with TROY synergistically promoted NF-κB activation. Mutation of the TRAF binding domain (TBD) in the cytoplasmic domain of TROY abolished its capacity to activate NF-κB, even in the presence of PDZ-RhoGEF, suggesting that the TBD is important for TROY induced NF-κB activation. Furthermore, knockdown of PDZ-RhoGEF by shRNA attenuated NF-κB activation in TROY expressing cells, blocked TROY mediated invasion of primary GBM xenograft cells and increased sensitivity to temozolomide. Collectively, these data indicate that PDZ-RhoGEF plays an important role in TROY signaling and provides insights into a potential node of vulnerability to limit GBM cell invasion and decrease therapeutic resistance. Citation Format: Zonghui Ding, Alison Roos, Jean Kloss, Harshil Dhruv, Marc Symons, Nhan L. Tran, Joseph C. Loftus. PDZ-RhoGEF functions as a critical signaling effector for TROY [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1878. doi:10.1158/1538-7445.AM2017-1878
A Man with Recurrent Ascites after Laparoscopic Cholecystectomy
Sepiashvili, Lusia, Dahl, Ashley R, Meeusen, Jeffrey W. , Loftus, Conor G., Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | June 28, 2017 | Volume: 63 | Issue: 7 | Pages: 1199-1202

10.1373/clinchem.2016.263756 | PMID 28659396 Get It

Immune modulator therapy for microscopic colitis in a case series of 73 patients
Cotter, Thomas G. , Kamboj, Amrit K. , Hicks, Stephen B., Tremaine, William J., Loftus, Edward V. , Pardi, Darrell S. , Cotter, T G , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 10, 2017 | Volume: 46 | Issue: 2 | Pages: 169-174

10.1111/apt.14133 | PMID 28488312 Get It

SummaryBackgroundMicroscopic colitis (MC) is a common cause of chronic diarrhoea. Various treatment options have been described, but there are limited data describing outcomes of corticosteroid‐sparing treatments.AimTo evaluate the outcomes of patients with active MC treated with immune modulators.MethodsAll patients seen at Mayo Clinic, Rochester between January 1, 1997 and November 30, 2016 with a histological diagnosis of MC were identified. Patients treated with an immune modulator of interest were selected and clinical outcomes recorded.ResultsSeventy‐three MC patients (50 collagenous colitis and 23 lymphocytic colitis) with a median disease duration of 24 months (range, 7‐60) were included. The indications for treatment were budesonide‐refractoriness in 66%, budesonide dependence in 29%, and budesonide intolerance in 5%. Median age was 51.8 years (range, 43.4‐63.1) and 61 (84%) were female. Thiopurines were used in 49 patients (67%) for a median of 4 months (range, 1.5‐15). Complete and partial response occurred in 43% and 22% respectively. Adverse effects resulting in therapy cessation occurred in 17 patients (35%). Twelve patients (16%) were treated with methotrexate for a median of 14 months (3‐18.8). Complete and partial response occurred in 58% and 17%, respectively. Anti‐TNF therapy was used in 10 patients (14%) for a median of 4 months (range, 2.3‐5.5). Complete response occurred in four patients and partial response in four patients.ConclusionsThe majority of patients with active MC responded to thiopurines, methotrexate, or anti‐TNF therapy. Larger controlled studies are required to confirm the efficacy and safety of these medications in MC.